StockData

Evotec vs Ultragenyx Pharmaceutical

EVO and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EVO and RARE compare

Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (17.5% versus −1.1% for Evotec).

Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 4 for Evotec), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEVORARE
Size and price
Market cap–$1.6B
Share price$1.48$16.70
Change, 1 year−51.0%−49.5%
Change, 5 years−93.8%−78.2%
Beta (5Y)2.222.12
Employees4,5531,371
StockData Score
Total score49 (better)
Valuation score01 (better)
Growth score12 (better)
Performance score01 (better)
Health score35 (better)
Dividend score00
Valuation
P/S–2.3×
FCF yield–−29.7%
Growth
Revenue growth (TTM)−1.1%17.5% (better)
Revenue growth, 5Y average9.5%19.9% (better)
Profitability
Gross margin14.5%–
Operating margin−7.1% (better)−73.6%
Net margin–−81.7%
FCF margin−10.4% (better)−68.2%
Return on invested capital−7.7%–
Financial health
Debt / equity0.10–
Net debt / EBITDA−7.79–
Current ratio2.07 (better)1.73
Altman Z-score–−5.26
Piotroski F-score–5
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions1.8%108%
Held by insiders17.1%4.0%
Insider net buying, 12 months–−$3.8M
Short interest, % of float–25.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.